Fulgent Genetics Inc - Company Profile
Powered by 
All the sales intelligence you need on Fulgent Genetics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fulgent Genetics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fulgent Genetics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Fulgent Genetics Inc (Fulgent) is a technology-based company engaged in laboratory services and therapeutic development. The company's main activities include providing technical laboratory and testing services, as well as developing drug candidates for cancer treatment. Fulgent offers a wide range of diagnostic and genetic tests, including comprehensive anatomic pathology and precision diagnostics testing services. Fulgent's products and services cater to patients, healthcare providers, pharmaceutical companies, and contract research organizations across various industries. The company operates through a network of CLIA-licensed laboratories in the United States. It offers genetic tests for cardiovascular and pediatric diseases, neurological disorders, and cancers, and primarily serves medical institutions and hospitals in the US, Canada, and other countries. Fulgent is headquartered in El Monte, California, the US.
Headquarters
United States of America
Address
4399 Santa Anita Ave, El Monte, California, 91731
Website
www.fulgentgenetics.com
Telephone
1 626 3500537
No of Employees
1,315
Industry
Medical Equipment
Ticker Symbol & Exchange
FLGT (NASD)
Revenue (2024)
$322.7M
13.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-41.7%
(2024 vs 2023)
Market Cap*
$513.2M
Net Profit Margin (2024)
XYZ
-24.4%
(2024 vs 2023)
* As of and is in US$
Fulgent Genetics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Genomic Testing | Sequencing | HelioLiver |
| Hereditary Cancer | Lab Services | Beacon |
| Carrier Screening | Gastrointestinal pathology | Lumera |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company entered into a partnership with Foundation Medicine, Inc. to introduce FoundationOne PGx, a pharmacogenetic offering to identify genetic differences. |
| 2026 | Acquisitions/Mergers/Takeovers | In March, the company acquired Bako Diagnostics, a pathology laboratory company. |
| 2026 | Acquisitions/Mergers/Takeovers | In March, the company acquired StrataDx, a dermatopathology laboratory. |
Competitor Comparison
| Key Parameters | Fulgent Genetics Inc | Labcorp Holdings Inc | Quest Diagnostics Inc | Exact Sciences Corp | Revvity Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | El Monte | Burlington | Secaucus | Madison | Waltham |
| State/Province | California | North Carolina | New Jersey | Wisconsin | Massachusetts |
| No. of Employees | 1,315 | 71,000 | 46,000 | 7,200 | 11,000 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ming Hsieh | President; Chief Executive Officer; Chairman | Executive Board | 2016 | 70 |
| Paul Kim | Chief Financial Officer | Senior Management | 2016 | 58 |
| James Xie | President; Chief Operating Officer | Senior Management | 2022 | 60 |
| Dr. Lawrence Weiss, M.D. | Chief Medical Officer | Senior Management | 2021 | - |
| Hanlin Gao, M.D., Ph.D. | Director - lab; Chief Scientific Officer | Senior Management | 2016 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer